Influenza Clinical Trial
Official title:
A Randomized, Blinded, Placebo-controlled, Cross-over Study of the Safety and Immunogenicity of Trivalent, Inactivated Influenza Vaccine for 2010-2011
The seasonal influenza vaccination program for 2010-2011 will be the first to follow the
H1N1 pandemic of 2009. Many Canadians either had the H1N1 infection or the adjuvanted H1N1
vaccine. Both H1N1 infection and adjuvanted vaccine produced strong immune responses which
could last for some time.
The seasonal influenza vaccine for this fall will be a "normal" product once again, without
adjuvant. It will contain 3 strains of killed, split-apart viruses that might circulate this
winter, including the H1N1 pandemic strain. It is theoretically possible that giving the
H1N1-containing seasonal vaccine to people who still have some immunity to H1N1 virus could
result in more frequent side-effects. However, there is no good evidence that pre-existing
immunity to a strain in the vaccine does increase side-effects. In short, there could be
nothing out of the ordinary this fall but it would be prudent to check this before public
flu vaccination programs begin.
This study will assess the safety of seasonal influenza vaccination in people who had the
adjuvanted H1N1 vaccine last year. It will also measure residual immunity to the H1N1 virus
and immune responses to the seasonal vaccine. It will be carried out before the new vaccine
is released for general use so that we have an accurate picture of vaccine safety and
responses for other Canadians.
A total of 320 adults (64 at each site) 20 to 59 years old, are being asked to participate
in this study. A research nurse will conduct a telephone screening with potential
participants to determine if they are eligible for the study. Volunteers must have had
adjuvanted H1N1 vaccine before January 31, 2010.
The study involves 2 vaccination visits 10 days part. At one visit seasonal vaccine will be
given and at the other a placebo vaccine will be given. Which vaccine is given first will be
determined by random chance, the details of which will not be released until study end.
After each vaccination, there will be contacts 1 and 7 days later for a description of any
symptoms experienced. A blood sample will be requested at the first and last visits (visit
3) to measure immune responses to the seasonal vaccine.
The study will take 21-38 days to complete, depending upon the vaccination sequence and
availability. Total time required to take part is about 2.5 hours. The 3 study visits will
occur at a clinic in Vancouver, Calgary, Ottawa, Montreal or Quebec City.
Each subject will be asked to keep daily notes of any changes at the injection site (pain,
redness, swelling) and any general symptoms (such as headache, tiredness, body aches),
including your oral temperature, for 7 days after each vaccination. Major health changes
will be assessed for 21 days post 'vaccination'
A special Safety Board will review the results of the first vaccinations and advise whether
it is reasonable to continue the study or not.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |